Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma

Anis, Shady E.; Lotfalla, Mira; Zain, Muhammad; Kamel, Nora N.; Soliman, Ahmed

doi:10.3889/oamjms.2018.062

Cited by 7 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Somatostatin receptor 2A was found to be a more sensitive diagnostic marker for meningioma than epithelial membrane antigen-a conventional meningioma marker (40). Since then, accumulating evidence has emerged to support the diagnosis value of SSTR2A as it is a highly sensitive and specific marker for meningioma (41,42). A case report has shown that SSTR2A, combined with epithelial membrane antigen, provides assistance for the diagnosis of an unusual skull tumor with psammomatoid bodies (43).…”

Section: Sstr2-related Diagnosis Approaches For Meningiomamentioning

confidence: 99%

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Zhou

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-proteincoupled receptor and can be activated by somatostatin or its synthetic analogs. SSTR2 is therefore extensively studied as a marker and target for the diagnosis and treatment of meningioma. Accumulating studies have revealed the crucial clinical significance of SSTR2 in meningioma. Summarizing the progress of these studies is urgently needed as it may not only provide novel and better management for patients with meningioma but also indicate the direction of future research. Pertinent literature is reviewed to summarize the recent collective knowledge and understanding of SSTR2's clinical significance in meningioma in this review. SSTR2 offers novel ideas and approaches in the diagnosis, treatment, and prognostic prediction for meningioma, but more and further studies are required.

show abstract

Section: Sstr2-related Diagnosis Approaches For Meningiomamentioning

confidence: 99%

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Zhou

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Interestingly both were also negative for SSTR2a, the most reliable meningioma marker. However, it has been previously reported that although all Grade 1 and 2 meningiomas are positive for SSTR2A, this is true for only 20% of Grade 3 meningiomas [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression

et al. 2023

View full text Add to dashboard Cite

Background A subset of meningiomas progress in histopathological grade but drivers of progression are poorly understood. We aimed to identify somatic mutations and copy number alterations (CNAs) associated with grade progression in a unique matched tumour dataset. Methods Utilising a prospective database, we identified 10 patients with meningiomas that had undergone grade progression and for whom matched pre- and post-progression tissue (n = 50 samples) was available for targeted next-generation sequencing. Results Mutations in NF2 were identified in 4/10 patients, of these 94% were non-skull base tumours. In one patient, three different NF2 mutations were identified in four tumours. NF2 mutated tumours showed large-scale CNAs, with highly recurrent losses in 1p, 10, 22q, and frequent CNAs on chromosomes 2, 3 and 4. There was a correlation between grade and CNAs in two patients. Two patients with tumours without detected NF2 mutations showed a combination of loss and high gain on chromosome 17q. Mutations in SETD2, TP53, TERT promoter and NF2 were not uniform across recurrent tumours, however did not correspond with the onset of grade progression. Conclusion Meningiomas that progress in grade generally have a mutational profile already detectable in the pre-progressed tumour, suggesting an aggressive phenotype. CNA profiling shows frequent alterations in NF2 mutated tumours compared to non NF2 mutated tumours. The pattern of CNAs may be associated with grade progression in a subset of cases.

show abstract

“…2 Schwannomas demonstrated notably low or absent 68 Ga-DOTATATE uptake, concordant with tissue studies demonstrating absence of SSTR expression in schwannomas by immunohistochemical staining. 16 For neuroaxis tumors with indeterminant MRI features and absent 68 Ga-DOTATATE uptake, schwannoma should be a primary consideration. All schwannomas ranged from an SUV max of 1 to 8.5.…”

Section: Discussionmentioning

confidence: 99%

68Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis

Hartmann,

Gillman,

Lazor

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

Aim The differentiation of paragangliomas, schwannomas, meningiomas, and other neuroaxis tumors in the head and neck remains difficult when conventional MRI is inconclusive. This study assesses the utility of 68Ga-DOTATATE PET/CT as an adjunct to hone the diagnosis. Patients and Methods This retrospective study considered 70 neuroaxis lesions in 52 patients with 68Ga-DOTATATE PET/CT examinations; 22 lesions (31%) had pathologic confirmation. Lesions were grouped based on pathological diagnosis and best radiologic diagnosis when pathology was not available. Wilcoxon rank sum tests were used to test for differences in SUVmax among paragangliomas, schwannomas, and meningiomas. Receiver operator characteristic curves were constructed. Results Paragangliomas had a significantly greater 68Ga-DOTATATE uptake (median SUVmax, 62; interquartile range [IQR], 89) than nonparagangliomas. Schwannomas had near-zero 68Ga-DOTATATE uptake (median SUVmax, 2; IQR, 1). Intermediate 68Ga-DOTATATE uptake was seen for meningiomas (median SUVmax, 19; IQR, 6) and other neuroaxis lesions (median SUVmax, 7; IQR, 9). Receiver operator characteristic analysis demonstrated an area under the curve of 0.87 for paragangliomas versus all other lesions and 0.97 for schwannomas versus all other lesions. Conclusions Marked 68Ga-DOTATATE uptake (>50 SUVmax) favors a diagnosis of paraganglioma, although paragangliomas exhibit a wide variability of uptake. Low to moderate level 68Ga-DOTATATE uptake is nonspecific and may represent diverse pathophysiology including paraganglioma, meningioma, and other neuroaxis tumors but essentially excludes schwannomas, which exhibited virtually no uptake.

show abstract

Value of SSTR2A and Claudin - 1 in Differentiating Meningioma from Schwannoma and Hemangiopericytoma

Cited by 7 publications

References 28 publications

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression

68Ga-DOTATATE PET to Characterize Lesions in the Neuroaxis

Contact Info

Product

Resources

About